This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix reports $11.5 million net loss in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix reported a net loss of $11.5 million, or $0.47 per share, in the third quarter compared with a net loss of $7.3 million, or $0.48, per share in the same quarter of 2014, according to a press release.

Product sales from ReSure sealant and other collaborations with corporate partners generated a revenue of $0.43 million in the third quarter. Approximately $0.14 million in revenue was recorded a year ago.

Operating expenses were reported at $11.6 million in the third quarter compared with $6.9 million in the same quarter of 2014. The increase was primarily attributed to personnel costs and clinical trials of Dextenza (sustained-release dexamethasone 0.4 mg) and OTX-TP (sustained-release travoprost ), as well as preclinical development of anti-VEGF and tyrosine kinase inhibitor programs for the treatment of wet age-related macular degeneration and other back of the eye diseases, the release said.